Veracyte (VCYT) closed at $24.06 on November 10, 2026, down 7.2% from the previous close, on volume of 4,021,239 shares (30-day average 1,876,909).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Call Diagonal Ratio Spread | 18-Dec-26 55[249x]|19-Mar-27 60[209x] C | 2,290 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Tue, 10-Nov 10:11 AM ET)
TipRanks (Mon, 9-Nov 5:45 PM ET)
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
Business Wire (Mon, 9-Nov 4:22 PM ET)
VCYT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Veracyte (VCYT)
ACCESS Newswire (Mon, 9-Nov 10:10 AM ET)
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and Veracyte (VCYT)
TipRanks (Mon, 9-Nov 9:01 AM ET)
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
PRNewswire (Fri, 6-Nov 10:13 AM ET)
PRNewswire (Thu, 5-Nov 7:34 PM ET)
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
Globe Newswire (Thu, 5-Nov 4:58 PM ET)
Veracyte downgraded at Leerink after guidance cut
Seeking Alpha News (Thu, 5-Nov 10:49 AM ET)
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Veracyte trades on the NASDAQ stock market under the symbol VCYT.
As of November 10, 2026, VCYT stock price declined to $24.06 with 4,021,239 million shares trading.
VCYT has a beta of 1.89, meaning it tends to be more sensitive to market movements. VCYT has a correlation of 0.06 to the broad based SPY ETF.
VCYT has a market cap of $1.92 billion. This is considered a Small Cap stock.
Last quarter Veracyte reported $152 million in Revenue and $.51 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.13.
In the last 3 years, VCYT traded as high as $60.91 and as low as $18.61.
The top ETF exchange traded funds that VCYT belongs to (by Net Assets): IJR, VTI, VB, XBI, FBT.
VCYT has underperformed the market in the last year with a price return of -42.3% while the SPY ETF gained +12.9%. VCYT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.0% and -50.1%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
VCYT support price is $24.95 and resistance is $26.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCYT shares will trade within this expected range on the day.
